Cynvenio Launches Clinical Trial For Breast Cancer Monitoring

Westlake Village-based cancer diagnostics developer Cynvenio Biosystems said it has launched a new clinical trial, which will use its technology to monitor women with triple negative breast cancer (TNBC) for early signs of metastasis. The company said the nationwide study is aimed at helping provide a better method to help patients monitor their health. The company said there is currently no effective way to monitor women who already have completed treatment for TNBC. Cynvenio said the new study will use its ClearID genomic test, in combination with the NK Vue blood test from ATGen Global. The company explained that TNBC patients are more likely to develop distant recurrence and die from breast cancer within five years of diagnosis compared with other patients, and one-third of those patients will eventually develop metastatic disease.